Vcanbio Cell & Gene Engineering

Vcanbio Cell & Gene Engineering, founded in 1995 (SSE: 600645), is a China-based company focused on precision medicine to benefit humanity. It operates in three core areas: precision prevention, precision diagnosis, and cell therapy, offering comprehensive health management services across the life cycle. The company aims to establish a precision medical industry platform, driving advancements in life sciences and enhancing global health standards through innovative solutions. Its primary business includes cell testing, preparation and storage, in vitro diagnostic materials, and clinical applications of stem cells and immune cells. Vcanbio Cell & Gene Engineering builds a precision healthcare ecosystem with a team size of 1,000-5,000 employees. Meet Vcanbio Cell & Gene Engineering's team to explore the expertise behind its operations and commitment to scientific advancement. Generating $219.9M in revenue, Vcanbio Cell & Gene Engineering holds a significant position in business services, particularly in life sciences and healthcare technology. While the provided data indicates a single primary location, the company's description highlights multiple subsidiaries globally, suggesting a broad operational footprint across Asia and the Asia-Pacific region. Its dedication to precision medicine positions it as a key player in the evolving healthcare landscape, translating scientific breakthroughs into tangible patient benefits and contributing to a healthier future.